ATHE Stock Latest News
Company AnnouncementsAlterity Therapeutics Files Form 6-K on Bell Potter Presentation1w ago6KATHE
Company AnnouncementsAlterity Therapeutics CEO to Highlight MSA Program at Craig-Hallum Biotech Catalyst Conference1M ago6KATHE
Company AnnouncementsAlterity Extends ATH434 Access, Reinforcing Its Bet on Rare MSA Market1M agoATHE
Company AnnouncementsAlterity Therapeutics Seeks Quotation of ATH Securities in August 20263M ago6KATHE
Company AnnouncementsAlterity Therapeutics Wins Long-Term U.S. Patent Protection for Lead MSA Drug ATH4343M ago6KATHE
Company AnnouncementsAlterity Therapeutics Files August 3 Application to Quote ATH Securities3M ago6KATHE
Company AnnouncementsAlterity Therapeutics Secures FDA Pathway and Bolsters Funding for ATH434 Phase 3 in MSA3M ago6KATHE
Company AnnouncementsAlterity Therapeutics Files Form 6-K and Seeks Quotation for ATH Securities4M ago6KATHE
Company AnnouncementsAlterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 20264M ago6KATHE
Company AnnouncementsAlterity Therapeutics Files July Form 6-K for Quotation of ATH Securities4M ago6KATHECompany AnnouncementsAlterity Therapeutics Discloses Change in Substantial Shareholding in June 2026 SEC Filing4M ago6KATHE








